secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001108205-25-000079
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q2 2025 net loss $8.6M; cash runway extended to Q1 2026 via $6M offering
------------------------------------------------------------------------------

- Net loss $8.6M ($0.68/sh) vs $11.8M ($2.03/sh) in Q2 2024; revenue $2.7M from Erivedge royalties.
- Cash and equivalents $10.1M at June 30, 2025; July 2025 offerings added ~$6M net proceeds.
- TakeAim Lymphoma study enrolling PCNSL patients to support US/EU accelerated approval; data expected later 2025.
- Adding proof-of-concept CLL study of emavusertib + BTKi in 20-30 R/R patients; enrollment to begin later 2025.
- TakeAim Leukemia Phase 1/2 enrollment complete; designing registrational trial vs gilteritinib in R/R AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/0001108205-25-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/cris-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001108205-25-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer